Dr. Aung Naing, MD
Claim this profileMD Anderson Cancer Center
Expert in Tumors
Expert in Solid Tumors
24 reported clinical trials
45 drugs studied
About Aung Naing, MD
Education:
- Obtained MD (Doctor of Medicine) from the University of Medicine 1, Yangon, Myanmar, in 1998.
- Completed Residency in Internal Medicine at the University of Texas Health Science Center at Houston in 2005.
- Finished Fellowship in Hematology/Oncology at the University of Texas MD Anderson Cancer Center in 2008.
Experience:
- Currently serves as a Professor in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center.
Area of expertise
1Tumors
Global LeaderStage IV
HLA positive
PD-L1 positive
2Solid Tumors
Global LeaderStage IV
Stage III
HLA positive
Affiliated Hospitals
Clinical Trials Aung Naing, MD is currently running
NM6603
for Cancer
This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.
Recruiting1 award Phase 112 criteria
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
More about Aung Naing, MD
Clinical Trial Related1 year of experience running clinical trials · Led 24 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Aung Naing, MD has experience with
- Pembrolizumab
- Toripalimab
- Nivolumab
- NM6603
- Avelumab
- Anti-OX40 Antibody PF-04518600
Breakdown of trials Aung Naing, MD has run
Tumors
Solid Tumors
Renal Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Aung Naing, MD specialize in?
Aung Naing, MD focuses on Tumors and Solid Tumors. In particular, much of their work with Tumors has involved Stage IV patients, or patients who are HLA positive.
Is Aung Naing, MD currently recruiting for clinical trials?
Yes, Aung Naing, MD is currently recruiting for 8 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Aung Naing, MD has studied deeply?
Yes, Aung Naing, MD has studied treatments such as Pembrolizumab, Toripalimab, Nivolumab.
What is the best way to schedule an appointment with Aung Naing, MD?
Apply for one of the trials that Aung Naing, MD is conducting.
What is the office address of Aung Naing, MD?
The office of Aung Naing, MD is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.